Related Experiment Video
Updated: Aug 16, 2026
LAD-Ligation: A Murine Model of Myocardial Infarction
Published on: October 14, 2009
Lats-IN-1 protects cardiac function and promotes regeneration after myocardial infarction by targeting the hippo
Hua Shen1,2, Qing Wang3, Bohan Liu1,2
1Department of Cardiovascular Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Insights
Lats-IN-1, a novel drug, promotes heart repair after myocardial infarction (MI) by activating the Hippo pathway. This treatment improves cardiac function and reduces cell death, offering hope for heart failure patients.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Molecular Biology
Background:
- Myocardial infarction (MI) leads to heart failure due to cardiomyocyte loss, limiting cardiac regeneration.
- The Hippo pathway regulates cell proliferation and apoptosis, presenting a therapeutic target for cardiac repair.
Purpose of the Study:
- To investigate the efficacy of Lats-IN-1, a LATS1/2 kinase inhibitor, as a novel treatment for MI.
- To evaluate Lats-IN-1's effects on cardiac function, infarct size, and cardiomyocyte survival.
Main Methods:
- Surgically induced MI in male C57BL/6 mice.
- Administration of Lats-IN-1.
- Assessment of cardiac function via echocardiography, infarct size, cardiomyocyte proliferation, and apoptosis assays.
Main Results:
- Lats-IN-1 significantly improved cardiac function, enhancing ejection fraction and reducing ventricular dimensions.
- Treatment decreased infarct size and cardiomyocyte apoptosis rates.
- Lats-IN-1 promoted cardiomyocyte proliferation, indicating cardiac repair and regeneration.
Conclusions:
- Lats-IN-1 modulates the Hippo pathway, reduces apoptosis, and promotes cardiac regeneration after MI.
- This inhibitor is a promising therapeutic strategy for heart diseases involving cardiomyocyte loss.
Introduction:
Myocardial infarction (MI), a leading cause of heart failure, is characterized by the loss of cardiomyocytes, which severely limits the heart's regenerative capacity. The Hippo pathway, which regulates cell proliferation and apoptosis, presents a therapeutic target for cardiac regeneration. This study explores the efficacy of Lats-IN-1, a LATS1/2 kinase inhibitor targeting the Hippo pathway, as a novel treatment for MI.
Methods:
Using male C57BL/6 mice subjected to surgically induced MI, we administered Lats-IN-1 and evaluated the effects on cardiac function, infarct size, cardiomyocyte proliferation, and apoptosis through various assays and echocardiographic assessments.
Results:
Our results demonstrate that Lats-IN-1 significantly improves cardiac function, as evidenced by enhanced ejection fraction and reduced ventricular dimensions. Additionally, Lats-IN-1 decreased infarct size and apoptosis rates while promoting cardiomyocyte proliferation. These findings suggest that Lats-IN-1 promotes cardiac repair and regeneration.
Discussion:
By modulating the Hippo pathway and reducing apoptosis markers, Lats-IN-1 represents a promising therapeutic strategy for improving outcomes in heart diseases characterized by cardiomyocyte loss. This study highlights the critical role of the Hippo pathway in facilitating cardiac regeneration.
